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Treatment in a Pediatric, Hemodialysis Patient:
A Case Report

Jason Koury, PharmD, BSN; Cintia Schnakenberg, PharmD; Charlotte Villasenor, PharmD; and Shirley Abraham, MD

Enoxaparin is a low molecular weight heparin (LMWH) that is the mainstay for treatment of pediatric
patients with a venous thromboembolism, which provides better compliance compared with the use of
unfractionated heparin (UFH) in long-term anticoagulation. Although data are limited in pediatric patients
with renal insufficiency, enoxaparin can be used in this population. Data related to its use in hemodialysis
(HD) pediatric patients is almost non-existent. A major concern for enoxaparin use in patients with renal
insufficiency or for those on HD is bleeding. A few studies in adults showed an increased risk of bleeding,
but the risk was similar to that of UFH when the two were compared. This case report describes the use of
enoxaparin in an 8-year-old female who is on hemodialysis, without any bleeding or clotting complications.
Although systematic trials are needed to support the safety and efficacy of LMWH in pediatric patients with
renal dysfunction or on HD, this case will provide limited information for enoxaparin use in this population.
ABBREVIATIONS CrCL, creatinine clearance; HD, hemodialysis; IRB, institutional review board; LMWH,
low molecular weight heparin; SVC, superior vena cava; UFH, unfractionated heparin; VTE, venous
thromboembolism
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Introduction
Enoxaparin is a low molecular weight heparin (LMWH)
that is the mainstay for anticoagulant treatment of pediatric patients with a venous thromboembolism (VTE)
because of its more predictable pharmacokinetics and
longer half-life when compared with those of unfractionated heparin (UFH). Enoxaparin is eliminated through
the kidneys, and it may accumulate when combined
with nephrotoxic medications in patients with acute or
chronic kidney injury or those on hemodialysis (HD).
For a pediatric patient who has a VTE and is on HD,
anticoagulation options are limited. Although UFH
would typically be the best option for a patient on HD,
subcutaneous heparin does not have a treatment indication in pediatric patients, and the dosing regimen
would need to be administered 3 times a day, which
presents compliance concerns in terms of long-term
anticoagulation.
Literature citing enoxaparin dosing and monitoring
is limited in the pediatric population for children who
have renal insufficiency and who are lacking in terms
of HD. The anecdotal consensus is to use enoxaparin
for chronic VTE treatment in patients with renal insufficiency. To ascertain information about LMWH prescribing patterns in children with renal insufficiency, a
survey was conducted among hematologists through
the Hemophilia and Thrombosis Research Society of
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North America.1 Seventy-seven percent of physicians
felt that LMWH could be prescribed safely in a patient
with renal insufficiency as long as anti-Xa concentrations were monitored. To our knowledge, in terms of
anticoagulation in pediatric patients on HD, data are
non-existent.
Anticoagulation treatment duration can often vary
among patients and disease-state characteristics. According to the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in Neonates
and Children,2 the recommended treatment duration for
a central venous access device–associated thrombus
is between 6 weeks and 3 months. In the interest of
providing additional information to support the body
of literature, we present a case study of enoxaparin
use in an 8-year-old female who was undergoing HD
and who was admitted for a superior vena cava (SVC)
thrombus secondary to a HD catheter. This study has
gone through the local institutional review board (IRB)
process and has been determined not to constitute
“human research.”

Case
An 8-year-old Caucasian female weighing 20 kg
presented to the University of New Mexico Hospital
with intermittent periorbital edema. Past medical history was significant for vertebral defects, anal atresia,
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cardiac defects, tracheo-esophageal fistula, renal
anomalies, and limb abnormalities syndrome and endstage renal disease on chronic HD. Echocardiogram
revealed an HD catheter thrombosis of the VTE, and
the pediatric hematology team was consulted for
management of the periorbital edema. On admission,
the patient underwent removal of the HD catheter
and angioplasty/fibrin sheath disruption of the SVC,
in which a clot was seen. A heparin drip was started
24 hours after the procedure at a rate of 20 units/kg/
hr with a goal activated partial thromboplastin time of
50 to 59 seconds. The heparin drip was titrated based
on the institution protocol to a target activated partial
thromboplastin time concentration ranging from 48
to 63 seconds. After 4 days of heparin, enoxaparin
20 mg (1 mg/kg) administered subcutaneously every
24 hours was begun, with a goal anti-Xa of 0.5 to 1
units/mL. The heparin drip was stopped at the time of
the first dose of enoxaparin, and the first anti-Xa was
drawn 4 hours after the second dose. Per hematology, a reevaluation by Doppler was scheduled after
6 weeks of enoxaparin therapy.
The patient was receiving high-flux dialysis 3 to 4
times per week without heparin for anticoagulation in
the circuit. Enoxaparin was dosed once daily throughout
the 6-week treatment duration and was timed for afternoon so that it would be administered after each dialysis
session. The first anti-Xa concentration was subtherapeutic, at 0.44 units/mL. Using enoxaparin prescribing
information, the dose was subsequently increased
by 10% to 22 mg (1.1 mg/kg) subcutaneously every 24
hours. The increase in enoxaparin dose resulted in an
anti-Xa concentration of 0.53 units/mL.3 Anti-Xa concentrations were checked after each dialysis session, and
repeat values were all therapeutic, ranging from 0.52
to 0.58 units/mL. Following discharged, home doses of
enoxaparin were drawn up by the local compounding
pharmacy to prevent potential dosing error and were
sent home with the family for administration. Based on
medical record notes and laboratory values, the patient
did not display signs or symptoms of bleeding or recurrent thrombosis. The 6-week repeat echocardiogram
was negative for an SVC thrombus, and enoxaparin
was discontinued.

Discussion
Low molecular weight heparin is a potential VTE
treatment option in patients with renal insufficiency
and HD, although literature to support this is limited,
and there is a potential for increased bleeding risk. In
our patient case, enoxaparin was used as an anticoagulation option for a HD catheter–induced thrombus.
Based on adult data on enoxaparin with a creatinine
clearance (CrCL) of <30 mL/min should have an empiric
dose adjustment to 1 mg/kg daily.3 In a pharmacokinetic
study of enoxaparin in pediatric patients published by
Moffett et al,4 a 30% reduction in starting dose was
www.jppt.org

Approach to Venous Thromboembolism Treatment

recommended in patients with a CrCL of <30 mL/min.
Given the limited available information, and by taking a
more conservative approach, the dose was reduced to 1
mg/kg daily, which was a 50% reduction. This reduction
ended up being appropriate because we only needed
to make one 10% adjustment up on the dose to gain
therapeutic concentrations.
A meta-analysis by Lim et al5 showed that anti-Xa
concentrations in adult patients receiving enoxaparin
treatment, with a CrCL of <30 mL/min, had concentrations ranging from 1.27 to 1.58 units/mL after a
minimum of 3 doses. Along with increased anti-Xa
concentrations, they showed an increase in major
bleeding in patients with a CrCL of <30 mL/min compared with in those with a CrCL of >30 mL/min (5.0%
vs 2.4%; OR, 2.25 [95% CI, 1.19 to 4.27]; p = 0.013). Data
are scarce for the use of LMWH in pediatric patients on
HD; therefore, data in adult patients can be used. Atiq
et al6 conducted a systematic review to investigate accumulation of prophylactic LMWH in adults with renal
dysfunction. Although enoxaparin was shown, based
on anti-Xa concentrations, to accumulate in instances
of renal dysfunction, patients who were on HD did
not accumulate enoxaparin. For patients on HD, antiXa concentrations drawn 4 hours post–prophylactic
enoxaparin dose were 0.38 units/mL at week 1 and
0.40 units/mL at week 4. These anti-Xa levels were
slightly elevated for prophylactic dosing, but they
also showed that enoxaparin was removed by HD.
The study did not mention details about the type of
HD circuit. It is important to note that although LMWH
is generally not cleared through HD, it is a possibility
with high-flux HD.
The risk of bleeding is a major concern with enoxaparin use in patients with renal dysfunction or in those
who are undergoing HD. A single-center, retrospective chart review conducted by Gerlach et al7 showed
a potential bleeding risk for adults who are taking
enoxaparin and have renal insufficiency. Total bleeding
complications occurred in 22% of patients with normal
renal function, compared with a rate of 51% in patients
with renal dysfunction (p < 0.01). Major bleeds were
also different, occurring in 2% and 30%, respectively (p
< 0.01), in patients with normal renal function and those
with renal dysfunction. Although a greater bleeding
risk was shown in the renal dysfunction group, it was a
small study, which made it difficult to establish causality
between enoxaparin and bleeding risk in renal patients.
Additional studies8,9 in adults have shown that enoxaparin has similar rates of bleeding when compared to
UFH for HD patients. Pon et al8 found a major bleeding
rate in adults on chronic HD of 6.1% vs 11% in enoxaparin
compared to UFH (p = 0.4). Although the data show that
the incidence of bleeding is similar between LMWH
and UFH patients, the studies were conducted in the
adult population, which makes it difficult to translate
the findings to the pediatric population.
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Conclusions
Based on this case report of a pediatric patient on
HD and on the published data, we were able to use
enoxaparin as VTE treatment while monitoring our
patient throughout her course using anti-Xa concentrations. A treatment dose of 1 mg/kg administered subcutaneously every 24 hours was sufficient to achieve
appropriate anti-Xa concentrations. Per the chart
review, our patient did not experience any bleeding
episodes or develop new SVC clots while undergoing
treatment, which was confirmed on echocardiogram.
For this patient, 6 weeks of therapy was sufficient, but
it is important to consider that duration of therapy could
have been extended if the clot was still present on ultrasound. As a result of dosing variability for pediatric
patients, having an outpatient pharmacy draw up the
doses would provide more accurate dosing and reduce
the risk of errors in instances of home use. Enoxaparin
provided an alternative to UFH for long-term anticoagulation in our patient, which is more practical in terms
of administration. Although it proved to be beneficial
in our case, larger prospective studies will be needed
to acquire more information and to establish it use in
anticoagulation guidelines in the pediatric population.
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